Navigation Links
WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
Date:6/28/2009

SHANGHAI, June 29 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had been selected by China's Ministry of Commerce to the list of Top Ten Leading Outsourcing Enterprises in China. The list was announced at the Second Annual China International Service Outsourcing Cooperation Conference, held in Nanjing on June 23 and 24, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

According to the ministry, revenue generated by Chinese outsourcing companies in 2008 grew 34% year over year to $1.5 billion. The top ten companies produced almost one third of that revenue. Those companies represented the healthcare, service and manufacture, government, education and finance sectors. WuXi PharmaTech was the only winner in healthcare.

"We are honored to receive this recognition by the Ministry of Commerce," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Outsourcing benefits not only China by tapping the skills and talents of our country's productive workforce, but also benefits countries around the world with high-quality, cost-effective products and services provided by outsourcing service companies. We are grateful to the Ministry of Commerce for its generous support of WuXi and the outsourcing industry in general. With continued support, we will continue to develop both capabilities and capacity to better serve the world's leading life science companies."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
2. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
3. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
7. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
8. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
11. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):